Regular exercise reduces the risk of 7 different kinds of cancer

Regular exercise reduces the risk of 7 different kinds of cancer is been found out in a study conducted by American cancer society, The National Cancer Institute & Harvard T.H.Chan School of public health.

Share This Post

A study conducted in the US found that regular exercise reduces the risk of 7 different types of cancer. This study was conducted by the American Cancer Society, The National Cancer Institute, & Harvard T.Chan School of public health. This study was published in Journal of Clinical Oncology.

Purpose of the study

To determine whether recommended amounts of leisure-time physical activity (i.e, 7.5-15 metabolic equivalent task [MET] hours/week) are associated with lower cancer risk, describe the shape of the dose-response relationship, and explore associations with moderate- and vigorous-intensity physical activity.

Result of the study

A total of 755,459 participants (median age, 62 years [range, 32-91 years]; 53% female) were followed for 10.1 years, and 50,620 incident cancers accrued. Engagement in recommended amounts of activity (7.5-15 MET hours/week) was associated with a statistically significant lower risk of 7 of the 15 cancer types studied, including colon (8%-14% lower risk in men), breast (6%-10% lower risk), endometrial (10%-18% lower risk), kidney (11%-17% lower risk), myeloma (14%-19% lower risk), liver (18%-27% lower risk), and Non-Hodgkin lymphoma (11%-18% lower risk in women). The dose response was linear in shape for half of the associations and nonlinear for the others. Results for moderate- and vigorous-intensity leisure-time physical activity were mixed. Adjustment for body mass index eliminated the association with endometrial cancer but had limited effect on other cancer types.
Regular exercise was specially linked to :

  • An 8% lower risk of colon cancer in men for 7.5 MET hours per week and a 14% lower risk for 15 MET hours per week
  • A 6% lower risk of breast cancer in women for 7.5 MET hours per week and a 10% lower risk for 15 MET hours per week
  • A 10% lower risk of endometrial cancer in women for 7.5 MET hours per week and an 18% lower risk for 15 MET hours per week
  • An 11% lower risk of kidney cancer for 7.5 MET hours per week and a 17% lower risk for 15 MET hours per week
  • A 14% lower risk of multiple myeloma for 7.5 MET hours per week and a 19% lower risk for 15 MET hours per week
  • An 18% lower risk of liver cancer for 7.5 MET hours per week and a 27% lower risk for 15 MET hours per week
  • An 11% lower risk of Non-Hodgkin lymphoma in women for 7.5 MET hours per week and an 18% lower risk for 15 MET hours per week

So it is true that regular exercise is a very potent weapon for cancer prevention. The proven cancer types that can be prevented are Colon cancer, Breast cancer, Endometrial cancer, Kidney cancer, Multiple Myeloma, Liver cancer, Myeloma, Non-Hodgkin Lymphoma.
Just by walking 30 minutes a day reduces these risks tremendously.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy